• Mashup Score: 1

    Author links open overlay panel Simone J. Dragsbaek a b, Mads D. Lyhne a c, Jacob V. Hansen a b, Christina C.E. Pedersen d, Takayuki Jujo-Sanada e f, Lina Karout g, Mannudeep K. Kalra g, Jens E. Nielsen-Kudsk a b, Asger Andersen a b Chronic thromboembolic pulmonary disease (CTEPD) with or without pulmonary hypertension (PH) at rest is a potential long-term complication from acute pulmonary embolism (PE) [1]. Unresolved clots can cause pulmonary arterial pressure increase, secondary microvasculopathy and

    Tweet Tweets with this article
    • Authors developed a porcine model of #ChronicThromboembolicPulmonaryDisease🐖🫁🫀Histological samples were compatible with #CTEPH patients🔬🩸 👉https://t.co/Q4PVjRC8wN @SimoneDragsbaek @MadsDam_MD @Jacob_V_Hansen @Lina_Karout1 @Nielsen_Kudsk @DocAsger @AUHCardio @AarhusUni_int https://t.co/gLiLWVG09j

  • Mashup Score: 1

    Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare complication of acute pulmonary embolism. Important advances have enabled better understanding, characterisation, and treatment of this condition. Guidelines recommending systematic follow-up after acute pulmonary embolism, and the insight that CTEPH can mimic acute pulmonary embolism on initial presentation, have led to the definition of CTEPH imaging characteristics, the introduction of artificial intelligence diagnosis pathways, and thus the prospect of easier and earlier CTEPH diagnosis.

    Tweet Tweets with this article
    • @madelcroix and colleagues describe treatment modalities targeting major vessel obstructions and microvasculopathy in chronic thromboembolic #PulmonaryHypertension, and outline a multimodal approach to management https://t.co/inoLsO3wBp #PH #CTEPH #PulmonaryEmbolism https://t.co/c9cHGYheMi

  • Mashup Score: 14

    The field of pulmonary hypertension has been transformed by advances in understanding of pathophysiological mechanisms and the development of a wide range of therapeutic options. The five main groups of pulmonary hypertension differ in epidemiology, causes and risk factors, underlying disease mechanisms, and clinical presentation. Approaches to diagnosis and management reflect the distinctive features of each condition. In the first of a Series of three papers, Marc Humbert and colleagues provide an

    Tweet Tweets with this article
    • The field of #pulmonaryhypertension has been transformed by advances in understanding of pathophysiological mechanisms and the development of a wide range of #therapeutic options Find out more in a new @LancetRespirMed Series https://t.co/ALcvKnFvoM #PH #PAH #CTEPH #COPD #ILD https://t.co/9xiHMp5yO4

  • Mashup Score: 0

    April 28, 2023 — A long-term analysis designed by Christian Gerges and Irene Lang at the Department of Medicine II of the University Hospital Vienna and MedUni Vienna indicates that one third of patients with chronic thromboembolic pulmonary hypertension (CTEPH) also have left heart disease. In the past, the possibility of overlap between these two conditions had not been considered in the…

    Tweet Tweets with this article
    • @DAICeditor @cardiovienna Long-term analysis at the Department of Medicine II of the University Hospital Vienna and MedUni Vienna indicates that one third of patients with chronic thromboembolic pulmonary hypertension (#CTEPH) also have left #heartdisease: https://t.co/zairbu9ueF

  • Mashup Score: 1

    In December 2021, I had pain, swelling, and bulging veins in my right arm. Doctors found blood clots in my subclavian and axillary veins.

    Tweet Tweets with this article
    • "In Jan. 2020, I was diagnosed with Hodgkin’s Lymphoma at 29. After 6 brutal months of chemo, my cancer was in remission. I was ready to return to 'normal' life. But my health continued to worsen..." Read Jessica's full story: https://t.co/V8prRQEJcx #stoptheclotstory #cteph https://t.co/agXFnurxNi

  • Mashup Score: 2

    This month’s JHLT: The Podcast is hosted by Digital Media Editor David Schibilsky, MD, who leads a discussion of two studies from the March issue of The Journal of Heart and Lung Transplantation—and the first authors who presented them.   First, the editors explore a study entitled “,” which comes from Hadinnapola and colleagues at the Papworth group in Cambridge, UK.   The editors welcome…

    Tweet Tweets with this article
    • Catch up on the March #JHLTThePodcast: 🧬Ang2 and hsCRP in #CTEPH/#PAH with @Charaka_H @RoyalPapworth 🫁 #EVLP and its impact on hospital costs in #LungTx with @johnpeel36 @UHNTransplant 🎧Listen on your favorite podcatcher or at https://t.co/qObbfKes5i https://t.co/0YjPBbontN